PPIDT00412

Drug Information
NameMargetuximab
SequenceNot Available
DrugBank_IDDB14967
Typebiotech
IndicationMargetuximab is an anti-HER2 monoclonal antibody indicated, in combination with chemotherapy, for the treatment of metastatic HER2-positive breast cancer in adult patients who have received two or more prior anti-HER2 regimens with at least one prior regimen for metastatic disease.[L27986]

Dosage Forms
Form Route Strength
Injection, solution, concentrate Intravenous
25 mg/1mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P04626 ERBB2 Receptor tyrosine-protein kinase erbB-2 Homo sapiens antagonist Link